Free Trial

Tevogen Bio (TVGNW) 10K Form and Latest SEC Filings 2026

Tevogen Bio logo
$0.04 0.00 (-4.78%)
As of 11:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Tevogen Bio SEC Filings & Recent Activity

Tevogen Bio (NASDAQ:TVGNW) has submitted 177+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 10-Q submitted on May 15, 2026.

Form 4
Tevogen Bio Holdings Inc. Reports Ownership Change on Mar. 17, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Tevogen Bio Files Current Report on Apr. 22, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Tevogen Bio Files Quarterly Report on May. 15, 2026

The 10-Q contains Tevogen Bio's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Tevogen Bio SEC Filing History

Browse Tevogen Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 4:01 PM
Tevogen Bio (1860871) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/30/2026 4:00 PM
Tevogen Bio (1860871) Filer
Form 10-K/A
04/22/2026 4:15 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/31/2026 4:16 PM
Tevogen Bio (1860871) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/25/2026 4:04 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2026 4:10 PM
Tevogen Bio (1860871) Filer
Form 424B3
03/17/2026 3:29 PM
Flomenberg Neal (2011757) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2026 8:08 AM
Tevogen Bio (1860871) Filer
Form 424B3
03/04/2026 8:04 AM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/26/2026 8:36 AM
Tevogen Bio (1860871) Filer
Form 424B3
02/06/2026 2:09 PM
Desai Kirti (2011765) Reporting
Tevogen Bio (1860871) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
This stock has 30 days of quiet left (Ad)

A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface. Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast.tc pixel

See the overlooked supplier before the SpaceX S-1 changes everything
01/30/2026 2:37 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/26/2026 4:29 PM
Tevogen Bio (1860871) Filer
Form DEF 14A
01/16/2026 4:29 PM
Tevogen Bio (1860871) Filer
Form PRE 14A
12/30/2025 9:12 AM
Desai Kirti (2011765) Reporting
Tevogen Bio (1860871) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/22/2025 4:43 PM
Saadi Ryan H. (2011728) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/16/2025 7:47 PM
Saadi Ryan H. (2011728) Filed by
Tevogen Bio (1860871) Subject
Form SCHEDULE 13D/A
12/15/2025 4:31 PM
Desai Kirti (2011765) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2025 5:51 PM
Saadi Ryan H. (2011728) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 8:22 AM
Tevogen Bio (1860871) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/14/2025 8:25 AM
Tevogen Bio (1860871) Filer
Form 424B3
09/26/2025 4:15 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2025 4:18 PM
Tevogen Bio (1860871) Filer
Form 424B3
07/25/2025 6:48 PM
Saadi Ryan H. (2011728) Filed by
Tevogen Bio (1860871) Subject
Form SCHEDULE 13D/A
07/10/2025 8:18 AM
Tevogen Bio (1860871) Filer
Form 424B3
07/10/2025 8:15 AM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/03/2025 4:23 PM
Tevogen Bio (1860871) Filer
Form 424B5
07/03/2025 4:25 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/01/2025 3:48 PM
Desai Kirti (2011765) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 3:49 PM
Flomenberg Neal (2011757) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 3:49 PM
Khan Sadiq (2011764) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/01/2025 3:49 PM
Saadi Ryan H. (2011728) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/30/2025 4:21 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/27/2025 4:26 PM
Tevogen Bio (1860871) Filer
Form 424B3
06/26/2025 11:15 PM
Tevogen Bio (1860871) Filer
Form EFFECT
06/23/2025 4:06 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/23/2025 4:09 PM
Tevogen Bio (1860871) Filer
Form 424B3
06/20/2025 4:20 PM
Tevogen Bio (1860871) Filer
Form S-3
Registration statement under Securities Act of 1933  
06/09/2025 6:13 PM
Saadi Ryan H. (2011728) Reporting
Tevogen Bio (1860871) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/09/2025 4:45 PM
Saadi Ryan H. (2011728) Reporting
Tevogen Bio (1860871) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2025 12:46 PM
Tevogen Bio (1860871) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Two scenarios for the dollar - gold wins in both cases (Ad)

Two scenarios are unfolding for the U.S. dollar right now - and both point toward gold. If a gold standard returns, gold would need to be repriced sharply higher to back the current money supply. If it doesn't, $39 trillion in national debt and continued dollar devaluation keep pushing gold the same direction it's already been heading. A legal IRA rollover lets you move a portion of your 401(k) or IRA into physical gold without triggering taxes or penalties. The free 2026 Gold IRA Guide walks through how both outcomes favor gold holders and how to position your retirement savings before the window narrows.tc pixel

Download the free 2026 Gold IRA Guide and see your options
06/03/2025 12:48 PM
Tevogen Bio (1860871) Filer
Form 424B3
(Data available from 1/1/2016 forward)

Tevogen Bio SEC Filings - Frequently Asked Questions

Tevogen Bio (TVGNW) has submitted 177+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 10-Q submitted on May 15, 2026. This was a quarterly financial update for 2025.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:TVGNW) was last updated on 5/27/2026 by MarketBeat.com Staff.
From Our Partners